RAPT Therapeutics appoints Scott Braunstein and Ashley Dombkowski to board, expands to 7 directors

RAPT Therapeutics, Inc.

Board expanded from 5 to 7; Drs. Braunstein and Dombkowski appointed as Class III directors with terms expiring at 2028 annual meeting.
Braunstein brings 30+ years pharma experience; currently operating partner at Aisling Capital, former CEO of Marinus Pharmaceuticals.
Dombkowski brings over 20 years operating & venture experience; current CEO of Cellics Therapeutics, former CEO of Alladapt Immunotherapeutics.
Each new director receives initial option grant of 25,000 shares and enters indemnification agreement; compensation policy amended.
Braunstein appointed to Audit Committee; Dombkowski to Nominating and Corporate Governance Committee.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Scott Braunstein, M.D.

Class III director

RAPT Therapeutics, Inc.

Effective: 2025-06-21
Filed: Jun 23, 2025 23:59 UTC

On June 21, 2025, the Board of Directors (the “Board”) of RAPT Therapeutics, Inc. (the “Company”) increased the size of the Board from five to seven directors and, upon the recommendation of its Nominating and Corporate Governance Committee, appointed Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D., as Class III directors of the Company, with terms expiring at the Company’s 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal.

Appointed

Ashley Dombkowski, Ph.D.

Class III director

RAPT Therapeutics, Inc.

Effective: 2025-06-21
Filed: Jun 23, 2025 23:59 UTC

On June 21, 2025, the Board of Directors (the “Board”) of RAPT Therapeutics, Inc. (the “Company”) increased the size of the Board from five to seven directors and, upon the recommendation of its Nominating and Corporate Governance Committee, appointed Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D., as Class III directors of the Company, with terms expiring at the Company’s 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal.

Source: SEC EDGAR

accession 0000950170-25-088715

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.